Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4226695 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY4226695 Part A | EXPERIMENTAL | Participants will receive LY4226695 or placebo administered subcutaneously (SC) |
| LY4226695 Part B | EXPERIMENTAL | Participants will receive LY4226695 or placebo administered SC |
| LY4226695 Part C | EXPERIMENTAL | Participants will receive LY4226695 or placebo administered SC |
| LY4226695 Part D | EXPERIMENTAL | Participants will receive LY4226695 administered intravenously (IV) |
| Name | Type | Description |
|---|---|---|
| LY4226695 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Have a screening body mass index (BMI) in the range of 18.5 to 35 kilograms per square meter (kg/m²), inclusive, with no significant weight gain or loss in the past 3 months prior to screening. * Individuals assigned male at birth must agree to adhere to contraception restrict...
LY4226695 is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with a single trial evaluating its effects in healthy volunteers. The drug is not approved for any indication and remains under investigation.
LY4226695 is being developed by Eli Lilly and Company, a biopharmaceutical company traded on the NYSE under the ticker LLY. The company is conducting a Phase 1 clinical trial of this small molecule in healthy participants.
LY4226695 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is designed to study the drug in healthy participants and is not yet recruiting.
LY4226695 is being studied in a single Phase 1 clinical trial with the identifier NCT07767487. The trial, titled 'A Study of LY4226695 in Healthy Participants,' is expected to enroll 148 participants and is conducted in the United States and Singapore.
LY4226695 is not FDA approved. It is an investigational small molecule currently in Phase 1 clinical development. The drug is being studied in healthy participants to evaluate its safety and tolerability, but it has not yet received regulatory approval for any use.